Observational studyPloS one2025
Impact of malaria vector control interventions implemented in Luangwa District southeastern of Zambia: A 13-year observational time series analysis of malaria trends.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLuangwa District has one of the longest running legacy datasets in Zambia regarding reliable monitoring of confirmed malaria cases through the national Health Management Information System (HMIS). It was also one of the first districts to achieve sustained coverage with long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) of insecticides.
methodsHMIS data from2009 to 2021 were analysed using generalized linear mixed models, to assess the effects of LLINs and IRS on rates of inpatient admissions with severe malaria and total confirmed malaria cases. IRS treatments included the pyrethroids deltamethrin and lambda-cyhalothrin, the organophosphate pirimiphos-methyl as emulsifiable concentrate and micro-encapsulated formulations (PM-EC and PM-CS, respectively) and a deltamethrin coformulation with the neonicotinoid clothianidin (DC).
resultsIRS with PM-CS reduced both inpatient admissions (Relative rates (RR) and 95% confidence intervals (CI) for ≤3 months, 4-6 months and 7-12 months post spray = 0.28 [0.19, 0.98] (P = 0.0019), 0.46 [0.31, 0.96] (P = 0.0346) and 0.41 [0.35, 0.94] (P = 0.0174), respectively), and total cases (RR [95%CI] = 0.25 [0.01, 0.67] (P = 0.0017), 0.66 [0.11, 0.88] (P = 0.0087) and 0.48 [0.28, 0.96] (P = 0.0018) for the same post-spray intervals, respectively) for a full year. Furthermore, while reductions of inpatient admissions with severe malaria could only be attributed to DC for the first three months after spraying (RR [95% CI] = 0.27 [0.10, 0.68], P = 0.0379), impacts upon total malaria cases were also apparent for a full year (RR [95% CI] for 1-3 months, 4-6 months and 7-12 months post spray = 0.15 [0.10, 0.68] (P = 0.0017), 0.23 [0.05, 0.56] (P = 0.0013) and 0.43 [0.25, 0.86], P = 0.0029, respectively). Overall, there were >90% fewer inpatient admissions and >80% fewer cases by the end of the study, much of which could be attributed to the immediate effects of scaling up IRS with PM-CS or DC in late 2014 (RR [95% CI = 0.36[0.26,0.51] per year, P = 0.0001) and simultaneously almost doubling the number of health facilities across the district in mid-2016 (RR [95% CI = 0.85 [0.76,0.96] per year, P = 0.0088).
conclusionsIRS with durable non-pyrethroid insecticide formulations and improved access to diagnosis and treatment were both clearly associated with substantial incremental reductions of malaria incidence. While no epidemiological effect could be attributed to LLINs, this presumably occurred because coverage was already high at the outset and remained so throughout the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.